Hypercorticism

Hypercorticism, more commonly known as Cushing's syndrome or hyperadrenocorticism, is an endocrine disorder in which the body produces chronically excessive amounts of cortisol. Cortisol is a steroid hormone manufactured by the adrenal glands that plays essential roles in metabolism, immune regulation, stress response, and blood sugar balance. Under normal circumstances, the hypothalamic-pituitary-adrenal axis tightly regulates cortisol output, but in hypercorticism that feedback loop is disrupted and cortisol levels remain persistently elevated.

The condition is one of the most frequently diagnosed endocrine disorders in middle-aged and older dogs. It develops gradually, and many owners initially attribute the early signs to normal aging. Because cortisol influences virtually every organ system, the consequences of prolonged overproduction are widespread and can significantly diminish a dog's quality of life if the condition goes unrecognized.

There are three principal forms of hypercorticism in dogs. Pituitary-dependent hyperadrenocorticism accounts for approximately 80 to 85 percent of naturally occurring cases and results from a benign tumor of the pituitary gland that secretes excessive adrenocorticotropic hormone. Adrenal-dependent hyperadrenocorticism, responsible for roughly 15 to 20 percent of cases, arises from a functional tumor on one of the adrenal glands. The third form, iatrogenic hypercorticism, is caused by long-term administration of exogenous corticosteroid medications.

Regardless of the underlying cause, the clinical picture is similar because the end result is the same: too much circulating cortisol. Early detection and appropriate management are critical, as sustained cortisol excess predisposes dogs to secondary complications including diabetes mellitus, urinary tract infections, hypertension, and thromboembolic disease.

The most common cause of naturally occurring hypercorticism in dogs is a pituitary microadenoma or macroadenoma. These benign tumors develop in the pars distalis or pars intermedia of the pituitary gland and autonomously secrete adrenocorticotropic hormone, which in turn drives the adrenal glands to produce excess cortisol. The pituitary tumor itself is usually small, but larger macroadenomas can expand upward and compress the brain, producing neurological signs in addition to endocrine dysfunction.

Adrenal-dependent hypercorticism is caused by a functional tumor within the adrenal cortex. These tumors may be adenomas, which are benign, or adenocarcinomas, which are malignant. Unlike pituitary-dependent disease, adrenal tumors produce cortisol independently of adrenocorticotropic hormone stimulation. The contralateral adrenal gland typically atrophies because chronically elevated cortisol suppresses pituitary secretion of adrenocorticotropic hormone, removing the trophic stimulus from the unaffected gland.

Iatrogenic hypercorticism develops when dogs receive prolonged courses of glucocorticoid medications such as prednisone, prednisolone, or dexamethasone. These medications are prescribed for conditions like allergies, immune-mediated diseases, and inflammatory disorders, and their long-term use can mimic the clinical syndrome of naturally occurring Cushing's disease. The iatrogenic form is fully reversible with gradual tapering and discontinuation of the offending medication.

Several risk factors increase the likelihood of developing hypercorticism. Age is a significant predictor, with most diagnoses occurring in dogs older than six years. Certain breeds carry a higher predisposition, including Poodles, Dachshunds, Boxers, Boston Terriers, Beagles, and Yorkshire Terriers. Although both sexes are affected, some studies suggest a slightly higher incidence in female dogs. Obesity does not cause hypercorticism but may coexist with it and complicate the clinical picture.

The clinical signs of hypercorticism develop insidiously over weeks to months, and their gradual onset often leads owners to attribute them to aging rather than disease. The most characteristic early signs are polydipsia and polyuria, meaning the dog drinks and urinates far more than normal. Owners frequently report that water bowls need constant refilling and that previously housetrained dogs begin having urinary accidents indoors, particularly overnight.

Increased appetite, or polyphagia, is another hallmark symptom. Dogs with hypercorticism may become ravenous, beg incessantly, raid garbage cans, or guard food aggressively. This increased caloric intake, combined with cortisol-driven redistribution of body fat, produces a characteristic pot-bellied appearance. The abdomen becomes pendulous due to fat deposition within the abdominal cavity, hepatomegaly from glycogen accumulation in the liver, and weakening of the abdominal musculature.

Dermatological changes are among the most visible manifestations of hypercorticism. Affected dogs often develop bilateral symmetrical hair loss that spares the head and limbs. The skin becomes thin and fragile, bruises easily, and may develop comedones, calcinosis cutis, or hyperpigmentation. Wound healing is markedly impaired, and secondary bacterial skin infections and ear infections are common because cortisol suppresses the immune system.

Additional signs include lethargy, exercise intolerance, muscle wasting, panting even at rest, and recurrent urinary tract infections. Some dogs develop a dull or dry coat before overt hair loss begins. In advanced cases, dogs may develop diabetes mellitus, systemic hypertension, pulmonary thromboembolism, or neurological signs if a pituitary macroadenoma compresses surrounding brain structures. The combination of several of these signs in a middle-aged or older dog should prompt veterinary evaluation for hypercorticism.

Diagnosing hypercorticism requires a systematic approach because no single test is definitive on its own. The process typically begins with a thorough history and physical examination, during which the veterinarian evaluates the constellation of clinical signs. A pot-bellied dog with thinning skin, hair loss, and excessive drinking and urination presents a classic picture, but laboratory confirmation is essential.

Routine blood work and urinalysis often reveal suggestive abnormalities. Complete blood counts may show a stress leukogram characterized by neutrophilia, lymphopenia, eosinopenia, and monocytosis. Serum chemistry panels frequently demonstrate elevated alkaline phosphatase, often dramatically so, along with elevated cholesterol, triglycerides, and blood glucose. Urinalysis typically reveals dilute urine with a low specific gravity, and urine culture may identify concurrent urinary tract infection.

Three primary screening tests are used to confirm hypercorticism. The urine cortisol-to-creatinine ratio is a sensitive screening test that can effectively rule out Cushing's disease when results are normal, but positive results require further testing because the test has low specificity. The low-dose dexamethasone suppression test is considered the gold standard screening test and involves measuring cortisol levels before and at four and eight hours after administering a low dose of dexamethasone. In healthy dogs, cortisol is suppressed; in dogs with hypercorticism, cortisol remains elevated. The ACTH stimulation test measures adrenal reserve by comparing baseline cortisol to cortisol levels one hour after synthetic adrenocorticotropic hormone injection and is also the test of choice for diagnosing iatrogenic hypercorticism.

Once hypercorticism is confirmed, differentiating between pituitary-dependent and adrenal-dependent forms is critical for treatment planning. Abdominal ultrasonography can visualize adrenal gland size and symmetry. Bilaterally enlarged adrenal glands suggest pituitary-dependent disease, while a unilateral adrenal mass with contralateral atrophy points to an adrenal tumor. The high-dose dexamethasone suppression test and measurement of endogenous adrenocorticotropic hormone concentrations provide further differentiation. Advanced imaging with computed tomography or magnetic resonance imaging may be recommended to evaluate pituitary gland size or characterize adrenal masses before surgical intervention.

Treatment of hypercorticism depends on the underlying cause, the dog's overall health, and the presence of concurrent conditions. For pituitary-dependent hypercorticism, the most widely used treatment is medical management with trilostane, a competitive inhibitor of the enzyme 3-beta-hydroxysteroid dehydrogenase that reduces cortisol synthesis in the adrenal glands. Trilostane is administered orally once or twice daily and requires regular monitoring through ACTH stimulation tests to ensure cortisol levels are adequately controlled without inducing hypoadrenocorticism.

Mitotane, also known as o,p'-DDD, is an older adrenolytic drug that selectively destroys the cortisol-producing zones of the adrenal cortex. It is used less frequently than trilostane due to its narrower therapeutic margin and greater potential for serious adverse effects, but remains an option for cases that do not respond adequately to trilostane. Mitotane therapy involves an initial loading phase followed by a maintenance dose, with cortisol levels monitored closely throughout treatment.

For adrenal-dependent hypercorticism caused by an adrenal tumor, surgical adrenalectomy is the treatment of choice when the tumor is amenable to removal. Surgery can be curative for benign adrenal adenomas and may significantly extend survival even in cases of adrenal carcinoma if the tumor has not metastasized. Adrenalectomy is a complex procedure that carries perioperative risks including hemorrhage and thromboembolic complications, so careful patient selection and experienced surgical teams are essential. Postoperative glucocorticoid supplementation is required because the contralateral adrenal gland will be atrophied and unable to produce adequate cortisol immediately.

Iatrogenic hypercorticism is managed by gradually tapering the exogenous corticosteroid medication under veterinary supervision. Abrupt withdrawal must be avoided because the hypothalamic-pituitary-adrenal axis will be suppressed and the dog may develop a life-threatening adrenal crisis. The tapering schedule is individualized based on the duration and dose of corticosteroid therapy. Radiation therapy may be considered for dogs with large pituitary macroadenomas causing neurological signs, as it can reduce tumor size and alleviate compression of surrounding brain tissue.

Long-term management of hypercorticism requires consistent monitoring to ensure treatment efficacy and detect complications early. Dogs receiving trilostane therapy typically undergo their first ACTH stimulation test 10 to 14 days after starting medication, with cortisol measured approximately four to six hours after the morning dose. The goal is to achieve a post-ACTH cortisol level within an optimal range that controls clinical signs without inducing cortisol deficiency.

Once the appropriate dose is established, ACTH stimulation tests are repeated at 30 days, 90 days, and then every three to six months for the duration of therapy. Electrolytes, renal values, and hepatic enzymes should be evaluated at each recheck to identify early signs of adrenal insufficiency or other metabolic derangements. Owners should be educated about the signs of cortisol deficiency, including lethargy, vomiting, diarrhea, loss of appetite, and collapse, as these warrant immediate veterinary attention and possible dose adjustment.

Clinical response to treatment is monitored alongside laboratory values. Owners typically notice improvement in water intake and urination within the first few weeks of treatment. Appetite normalization, increased energy levels, and skin and coat improvements follow over subsequent weeks to months. Hair regrowth may take three to six months, and some dogs may never fully regain their previous coat density. Resolution of the pot-bellied appearance occurs gradually as hepatomegaly decreases and abdominal musculature strengthens.

Dogs with hypercorticism should also be screened regularly for secondary conditions. Blood pressure monitoring helps detect systemic hypertension, which may require separate treatment. Urine cultures should be performed periodically even in the absence of urinary symptoms, as cortisol-induced immunosuppression predisposes to subclinical urinary tract infections. Blood glucose monitoring is important because some dogs with Cushing's disease develop concurrent diabetes mellitus, which may resolve or persist after cortisol levels are controlled.

Untreated or poorly controlled hypercorticism predisposes dogs to a range of serious complications that can significantly affect morbidity and mortality. One of the most dangerous complications is pulmonary thromboembolism, which occurs because chronic cortisol excess creates a hypercoagulable state. Blood clots that form in the venous system can travel to the lungs, causing acute respiratory distress, collapse, and potentially death. This complication can occur suddenly and without warning, even in dogs that otherwise appear stable.

Diabetes mellitus develops in a subset of dogs with hypercorticism because cortisol promotes insulin resistance and stimulates hepatic gluconeogenesis. In some cases, the diabetes resolves once cortisol levels are normalized through treatment, but in others, permanent pancreatic beta cell damage has occurred and lifelong insulin therapy becomes necessary. Managing concurrent Cushing's disease and diabetes is clinically challenging and requires careful coordination of both treatment protocols.

Systemic hypertension is another common complication, affecting a significant proportion of dogs with hypercorticism. Sustained high blood pressure can damage target organs including the eyes, kidneys, heart, and brain. Ocular consequences may include retinal detachment and hemorrhage leading to acute blindness. Renal damage from hypertension can compound proteinuria already present from glomerular changes induced by cortisol excess.

Recurrent infections are a hallmark of hypercorticism because cortisol suppresses both innate and adaptive immune function. Urinary tract infections are particularly common and may be subclinical, meaning the dog shows no obvious symptoms despite significant bacterial colonization. Skin infections, including bacterial pyoderma and demodicosis, occur frequently due to the combination of immunosuppression and thinned, fragile skin. Calcinosis cutis, a painful condition in which calcium deposits form within the skin, can develop in severe cases and is difficult to resolve until cortisol levels are controlled.

While dietary management alone cannot control hypercorticism, nutritional support plays an important role in the overall treatment plan. Dogs with Cushing's disease benefit from a diet that is moderate in fat and controlled in calories to help manage the weight gain and abdominal fat deposition associated with cortisol excess. High-quality, easily digestible protein sources support muscle maintenance and help counteract the catabolic effects of cortisol on skeletal muscle tissue.

Because hypercorticism is associated with increased urinary calcium excretion and impaired calcium metabolism, attention to mineral balance in the diet is warranted. Some veterinary nutritionists recommend diets with controlled calcium and phosphorus levels to reduce the risk of urinary calculi, which can occur secondary to altered mineral excretion. Adequate hydration is important given the increased urine output associated with the disease, and fresh water should be available at all times. Restricting water access in an attempt to reduce urination is contraindicated and can lead to dehydration.

Exercise should be tailored to the individual dog's condition and tolerance. Dogs with hypercorticism often experience muscle weakness and exercise intolerance, so activity should be gentle and gradually increased as treatment takes effect and strength improves. Low-impact activities such as leashed walks on flat terrain are preferable to strenuous play or activities that stress the joints and muscles. As cortisol levels normalize with treatment, many dogs regain stamina and can resume more vigorous activity.

Environmental management considerations include providing easy access to outdoor areas for frequent urination, using waterproof bedding if accidents occur, and monitoring for signs of skin breakdown or infection in dogs with thin, fragile skin. Owners should avoid rough grooming practices and be cautious with collars or harnesses that may abrade the skin. Reducing stressful situations when possible is also beneficial, as physiological stress can further stimulate the hypothalamic-pituitary-adrenal axis.

Hypercorticism can occur in any breed of dog, but epidemiological studies have consistently identified certain breeds with higher prevalence rates. Poodles, particularly Miniature and Toy varieties, are among the most commonly affected breeds. Dachshunds, Beagles, Boston Terriers, Boxers, and Yorkshire Terriers also demonstrate increased susceptibility. Among larger breeds, German Shepherds, Labrador Retrievers, and various terrier breeds are represented in case populations, though the condition overall shows a predilection for small to medium-sized dogs.

The age of onset is typically six years or older, with the majority of diagnoses occurring between 8 and 12 years of age. It is rare in dogs younger than four years, and cases diagnosed in young dogs should prompt thorough investigation for adrenal tumors or unusual pituitary pathology. Both male and female dogs are affected, though some studies have reported a slight female predisposition for pituitary-dependent disease while adrenal tumors may be more equally distributed between sexes.

The prevalence of hypercorticism in the general canine population has been estimated at approximately one to two cases per 1,000 dogs, though the true prevalence may be higher because mild or early cases may go undiagnosed. Increased awareness among veterinarians and pet owners, combined with improved diagnostic testing, has led to more frequent identification of the condition over the past several decades. Geographic variation in diagnosis rates likely reflects differences in veterinary access and awareness rather than true differences in disease incidence.

The breed predisposition strongly suggests a genetic component to pituitary-dependent hypercorticism, though the specific genetic mechanisms remain incompletely understood. Research has explored potential hereditary factors in certain breeds, and familial clustering of cases has been reported in some breeding lines. Understanding the genetic basis of susceptibility could eventually lead to screening tools and breeding strategies that reduce the incidence of the disease in high-risk populations.

The prognosis for dogs with hypercorticism varies depending on the underlying cause, the presence of complications, and how well the condition responds to treatment. Dogs with pituitary-dependent hypercorticism that respond well to medical management with trilostane or mitotane can have a good quality of life and may survive for two to four years or longer after diagnosis. Many owners report significant improvement in their dog's demeanor, energy, and comfort within the first few months of treatment.

Adrenal-dependent hypercorticism caused by a benign adenoma carries a favorable prognosis if the tumor is successfully removed surgically. Dogs that undergo uncomplicated adrenalectomy for adenomas may be considered cured, with normal life expectancy possible. The prognosis for adrenal carcinoma is more guarded and depends heavily on whether metastasis has occurred at the time of diagnosis. Even with successful tumor removal, recurrence and metastatic disease remain concerns with malignant adrenal tumors.

Iatrogenic hypercorticism generally carries an excellent prognosis because the condition is fully reversible once exogenous corticosteroids are gradually discontinued. Recovery of normal hypothalamic-pituitary-adrenal axis function may take weeks to months depending on the duration and intensity of prior corticosteroid therapy, but most dogs eventually regain normal cortisol regulation.

Quality of life assessments should be ongoing throughout the course of treatment. Key indicators of good quality of life include normalized water intake and urination, restored appetite without ravenousness, improved energy and willingness to engage in activities, and gradual improvement of skin and coat condition. Dogs that develop refractory complications such as uncontrolled diabetes, recurrent thromboembolism, or neurological deterioration from pituitary tumor growth may experience diminished quality of life despite treatment. Open communication between owners and veterinarians about realistic expectations, treatment goals, and end-of-life considerations is an important aspect of managing this chronic condition.